Tech Company Financing Transactions
PMV Pharmaceuticals Funding Round
PMV Pharmaceuticals, based in Cranbury, secured $74 million in investment from Topspin Partners, Euclid Opportunities and InterWest Partners.
Transaction Overview
Company Name
Announced On
2/23/2017
Transaction Type
Venture Equity
Amount
$74,000,000
Round
Series B
Investors
Topspin Partners (Lead Investor) (Steve Winick)
OrbiMed (Peter Thompson)
Proceeds Purpose
The proceeds will be used to develop and advance into the clinic the Company's pipeline of mutant p53 restoration drug candidates.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
8 Clarke Dr. 3
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Undisclosed
Website
Email Address
Overview
PMV Pharmaceuticals (Nasdaq: PMVP) is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV combines unique biological understanding with pharmaceutical development focus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Mack
Chief Medical Officer
Leila Alland
Chief Operating Officer
Winston Kung
Vice President
Thomas Davis
Vice President
Melissa Dumble
Vice President
Binh Vu
VP - Regulatory Affairs
Deepika Jalota
Browse more venture capital transactions:
Prev: 2/23/2017: Oncternal Therapeutics venture capital transaction
Next: 2/23/2017: Mailgun venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs